The first U.S. application for sale of a nonprescription birth control pill has taken on new meaning in the wake of the Supreme Court decision ending the constitutional right to abortion.
Agency inspectors found a leaking roof, standing water and cracked production equipment before a facility shutdown that led to major shortages.
With just a handful of companies making U.S. infant formula, a shutdown of Abbott’s plant had outsized impact on the supply.
The narrow 50-46 decision underscored the divisions on both sides of the aisle over agency policies on opioids and abortion medications and his ties to the drug industry.
President Biden came into office vowing to respect science, but openings in crucial jobs could hamper progress on medical and technological research.
Dr. Robert Califf, a former agency commissioner, is encountering opposition over federal opioid and abortion policies and his industry ties.
A key committee was split mainly on party lines over the nomination of Dr. Robert Califf, foreshadowing divisions in the full Senate for a vote on confirmation.
A Senate panel hearing on Tuesday signaled that Dr. Robert Califf, who briefly led the agency during the Obama administration, had some bipartisan support.
Dr. Robert M. Califf, an academic and clinical trial researcher who ran the agency in 2016, has also consulted for pharmaceutical companies.
The F.D.A. has been without a permanent chief since President Biden took office.